Meanwhile, the New Zealand Self-Medication Industry Association said it felt disappointed at the government's decision to drop ANZTPA. The SMI executive director, Tim Roper, said a single regulatory body was the aspiration of the organisation for a number of years.
The regulators were hoping to get ANZTPA in place by 2017 before this new decision came up for scrapping it.
The role of ANZTPA will be to safeguard public health and safety through the regulation of the quality, safety and efficacy of therapeutic products in both Australia and New Zealand.
The ANZTPA definition of therapeutic products embraces complementary medicines, prescription drugs, over-the-counter pharmaceutical medicines, medical devices, human blood and other products intended for therapeutic use.
ANZTPA will operate, more or less, along the same regulatory arrangements that have existed in Australia since 1989.
where FDA has a regulatory responsibility for both dietary supplements and food, Australia and New Zealand have two distinct regulatory authorities, one for dietary supplements (ANZTPA
) and one for food and beverage (FSANZ).
Despite the discontinuation, the two countries vowed to "continue to cooperate on the regulation of therapeutic products where there are benefits for consumers, businesses and regulators." In a(https://www.health.gov.au/internet/main/publishing.nsf/Content/407F341155162622CA257BF0001C965B/$File/ANZTPA%20Factsheet.pdf) factsheet , the ANZTPA has been described as an agency that will "safeguard public health and safety, while encouraging economic integration and benefitting industry in both countries."
Had it pushed through, the ANZTPA will be the one to regulate complementary medicines, over-the-counter medicines, prescription medicines, medical devices, blood and blood products, tissues and cellular therapies.
The agreement for the creation of the ANZTPA was first reached in 2003.